Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants

Texto completo
Autor(es):
Mostrar menos -
Shi, Xiaoguang [1] ; Liu, Rengyun [1] ; Basolo, Fulvio [2] ; Giannini, Riccardo [2] ; Shen, Xiaopei [1] ; Teng, Di [1] ; Guan, Haixia [3, 4] ; Shan, Zhongyan [3, 4] ; Teng, Weiping [3, 4] ; Musholt, Thomas J. [5] ; Al-Kuraya, Khawla [6] ; Fugazzola, Laura [7, 8] ; Colombo, Carla [7, 8] ; Kebebew, Electron [9] ; Jarzab, Barbara [10] ; Czarniecka, Agnieszka [10] ; Bendlova, Bela [11] ; Sykorova, Vlasta [11] ; Sobrinho-Simoes, Manuel [12, 13] ; Soares, Paula [12, 13] ; Shong, Young Kee [14] ; Kim, Tae Yong [14] ; Cheng, Sonia [15] ; Asa, Sylvia L. [15] ; Viola, David [16] ; Elisei, Rossella [16] ; Yip, Linwah [17] ; Mian, Caterina [18] ; Vianello, Federica [19] ; Wang, Yangang [20] ; Zhao, Shihua [20] ; Oler, Gisele [21] ; Cerutti, Janete M. [21] ; Puxeddu, Efisio [22] ; Qu, Shen [23] ; Wei, Qing ; Xu, Huixiong [24] ; O'Neill, Christine J. [25] ; Sywak, Mark S. [25] ; Clifton-Bligh, Roderick [25] ; Lam, Alfred K. [26] ; Riesco-Eizaguirre, Garcilaso [27, 28, 29, 30] ; Santisteban, Pilar [29, 30] ; Yu, Hongyu [31] ; Tallini, Giovanni [32] ; Holt, Elizabeth H. [33] ; Vasko, Vasily [34] ; Xing, Mingzhao [1]
Número total de Autores: 48
Afiliação do(s) autor(es):
Mostrar menos -
[1] Johns Hopkins Univ, Sch Med, Div Endocrinol Diabet & Metab, Lab Cellular & Mol Thyroid Res, Dept Med, Baltimore, MD 21287 - USA
[2] Dept Surg, Div Pathol, I-56126 Pisa - Italy
[3] China Med Univ, Hosp 1, Endocrine Inst, Shenyang 110001, Liaoning - Peoples R China
[4] China Med Univ, Hosp 1, Dept Endocrinol & Metab, Liaoning Prov Key Lab Endocrine Dis, Shenyang 110001, Liaoning - Peoples R China
[5] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Endocrine Surg, D-55101 Mainz - Germany
[6] King Faisal Specialist Hosp & Res Ctr, Res Ctr, Human Canc Genom Res, Riyadh 12713 - Saudi Arabia
[7] IRCCS Ca Granda Policlin, Fdn Inst Ricovero & Cura Carattere Sci, Milan - Italy
[8] Univ Milan, Dept Pathophysiol & Transplantat, I-20122 Milan - Italy
[9] NCI, Endocrine Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 - USA
[10] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, PL-44101 Gliwice - Poland
[11] Inst Endocrinol, Dept Mol Endocrinol, Prague 11694 - Czech Republic
[12] Univ Porto Ipatimup, Inst Mol Pathol & Immunol, P-4200319 Oporto - Portugal
[13] Univ Porto, Fac Med, P-4200319 Oporto - Portugal
[14] Univ Ulsan, Coll Med, Seoul - South Korea
[15] Univ Hlth Network, Dept Pathol, Toronto, ON M5G 2C4 - Canada
[16] Univ Pisa, WHO, Endocrine Unit, Dept Clin & Expt Med, Collaborating Ctr Study & Treatment Thyroid Dis &, I-56124 Pisa - Italy
[17] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 - USA
[18] Univ Padua, Endocrinol Unit, Dept Med, I-35128 Padua - Italy
[19] IRCCS, Veneto Inst Oncol, I-35128 Padua - Italy
[20] Qingdao Univ, Affiliated Hosp, Dept Endocrinol, Qingdao 266003 - Peoples R China
[21] Univ Fed Sao Paulo, Div Genet, Genet Bases Thyroid Tumor Lab, BR-04039032 Sao Paulo - Brazil
[22] Univ Perugia, Dept Internal Med, I-06100 Perugia - Italy
[23] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Endocrinol, Thyroid Inst, Shanghai 200072 - Peoples R China
[24] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Med Ultrasound, Thyroid Inst, Shanghai 200072 - Peoples R China
[25] Univ Sydney, Endocrine Surg Unit, Sydney, NSW 2052 - Australia
[26] Griffith Univ Gold Coast, Canc Mol Pathol Menzies Hlth Inst Queensland, Southport, Qld 4215 - Australia
[27] Hosp La Paz, Hlth Res Inst, Madrid 28029 - Spain
[28] Hosp Univ Mostoles, Madrid 28029 - Spain
[29] CSIC, Spanish Council Res, Biomed Res Inst, Alberto Sols, Madrid 28029 - Spain
[30] Autonomous Univ Madrid, Madrid 28029 - Spain
[31] Second Mil Med Univ, Changzheng Hosp, Dept Pathol, Shanghai 200003 - Peoples R China
[32] Univ Bologna, Osped Bellaria, Anat Pathol Unit, Dept Med, I-40139 Bologna - Italy
[33] Yale Univ, Sch Med, Dept Internal Med, Endocrine Sect, New Haven, CT 06520 - USA
[34] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 - USA
Número total de Afiliações: 34
Tipo de documento: Artigo Científico
Fonte: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM; v. 101, n. 1, p. 263-273, JAN 2016.
Citações Web of Science: 74
Resumo

Context: Individualized management, incorporating papillary thyroid cancer (PTC) variant-specific risk, is conceivably a useful treatment strategy for PTC, which awaits comprehensive data demonstrating differential risks of PTC variants to support. Objective: This study sought to establish the differential clinicopathological risk of major PTC variants: conventional PTC (CPTC), follicular-variant PTC (FVPTC), and tall-cell PTC (TCPTC). Methods: This was a retrospective study of clinicopathological outcomes of 6282 PTC patients (4799 females and 1483 males) from 26 centers and The Cancer Genome Atlas in 14 countries with a median age of 44 years (interquartile range, 33-56 y) and median follow-up time of 37 months (interquartile range, 15-82 mo). Results: The cohort consisted of 4702 (74.8%) patients with CPTC, 1126 (17.9%) with FVPTC, and 239 (3.8%) with TCPTC. The prevalence of high-risk parameters was significantly different among the three variants, including extrathyroidal invasion, lymph node metastasis, stages III/IV, disease recurrence, mortality, and the use (need) of radioiodine treatment (all P < .001), being highest in TCPTC, lowest in FVPTC, and intermediate in CPTC, following an order of TCPTC > CPTC >> FVPTC. Recurrence and mortality in TCPTC, CPTC, and FVPTC were 27.3 and 6.7%, 16.1 and 2.5%, and 9.1 and 0.6%, corresponding to events per 1000 person-years (95% confidence interval {[}CI]) of 92.47 (64.66-132.26) and 24.61 (12.31-49.21), 34.46 (30.71-38.66), and 5.87 (4.37-7.88), and 24.73 (18.34-33.35) and 1.68 (0.54-5.21), respectively. Mortality hazard ratios of CPTC and TCPTC over FVPTC were 3.44 (95% CI, 1.07-11.11) and 14.96 (95% CI, 3.93-56.89), respectively. Kaplan-Meier survival analyses showed the best prognosis in FVPTC, worst in TCPTC, and intermediate in CPTC in disease recurrence-free probability and disease-specific patient survival. This was particularly the case in patients at least 45 years old. Conclusion: This large multicenter study demonstrates differential prognostic risks of the three major PTC variants and establishes a unique risk order of TCPTC > CPTC >> FVPTC, providing important clinical implications for specific variant-based management of PTC. (AU)

Processo FAPESP: 12/02902-9 - Investigação do papel dos microRNAs na regulação da expressão do gene C1orf24 em tumores da tiróide humana
Beneficiário:Janete Maria Cerutti
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 13/03867-5 - Análise da variação no número de cópias (CNV) de segmentos de DNA em pacientes de uma família com síndrome nem 2ª e mutação p.G533C no gene RET: identificação de regiões associadas à gênese e progressão do carcinoma medular da tiróide
Beneficiário:Janete Maria Cerutti
Linha de fomento: Auxílio à Pesquisa - Regular